Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -19,314 | -12,032 | -5,772 | -26,767 | -20,890 |
| Depreciation Amortization | 55 | 37 | 17 | 272 | 238 |
| Accounts receivable | 46 | 30 | 17 | 31 | 63 |
| Other Working Capital | -75 | 376 | -106 | -680 | -1,409 |
| Other Operating Activity | 5,764 | 3,128 | 861 | 8,854 | 7,728 |
| Operating Cash Flow | $-13,523 | $-8,462 | $-4,982 | $-18,289 | $-14,270 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -13 | -8 | -16 | -11 |
| Investing Cash Flow | $-16 | $-13 | $-8 | $-16 | $-11 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 25 | 25 | N/A | 15,715 | 130 |
| Other Financing Activity | -30 | -20 | -10 | -1,965 | -20 |
| Financing Cash Flow | $-5 | $5 | $-10 | $13,750 | $110 |
| Exchange Rate Effect | -218 | -484 | -75 | 1,379 | 210 |
| Beginning Cash Position | 22,198 | 22,109 | 21,296 | 25,493 | 25,605 |
| End Cash Position | 8,437 | 13,155 | 16,221 | 22,317 | 11,644 |
| Net Cash Flow | $-13,761 | $-8,954 | $-5,075 | $-3,176 | $-13,961 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,523 | -8,462 | -4,982 | -18,289 | -14,270 |
| Capital Expenditure | -16 | -13 | -8 | -16 | -11 |
| Free Cash Flow | -13,539 | -8,476 | -4,990 | -18,305 | -14,281 |